Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

Agampodi Danushi M. Gunasekara, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nguyen T. Ha, Gareth J. McKay, John Attia and Ammarin Thakkinstian

Simple Summary: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer causes more aggressive progression of disease and poorer outcomes for patients. HER2-targeted medicines used as neoadjuvant systemic therapy could improve clinical outcomes in early-stage or locally advanced breast cancer patients. The purpose of this systematic review and network meta-analysis was to identify the neoadjuvant anti-HER2 therapy with the best balance between efficacy and safety. We found that trastuzumab emtansine + pertuzumab + chemotherapy had a high pathologic complete response with a low risk of adverse events compared to other neoadjuvant anti-HER2 regimens, while the pertuzumab + trastuzumab + chemotherapy regimen showed the highest disease-free survival. However, further trial data on neoadjuvant regimens with trastuzumab emtansine are needed to confirm these findings.

Abstract: This systematic review aimed to identify neoadjuvant anti-human epidermal growth factor receptor 2 (HER2) therapies with the best balance between efficacy and safety. Methods: A network meta-analysis was applied to estimate the risk ratios along with 95% confidence intervals (CIs) for pathological complete response (pCR) and serious adverse events (SAE). A mixed-effect parametric survival analysis was conducted to assess the disease-free survival (DFS) between treatments. Results: Twenty-one RCTs with eleven regimens of neoadjuvant anti-HER2 therapy (i.e., trastuzumab + chemotherapy (TC), lapatinib + chemotherapy (LC), pertuzumab + chemotherapy (PC), pertuzumab + trastuzumab (PT), trastuzumab emtansine + pertuzumab (T-DM1P), pertuzumab + trastuzumab + chemotherapy (PTC), lapatinib + trastuzumab + chemotherapy (LTC), trastuzumab emtansine + lapatinib + chemotherapy (T-DM1LC), trastuzumab emtansine + pertuzumab + chemotherapy (T-DM1PC), PTC followed by T-DM1P (PTC_T-DM1P), and trastuzumab emtansine (T-DM1)) and chemotherapy alone were included. When compared to TC, only PTC had a significantly higher DFS with a hazard ratio (95% CI) of 0.54 (0.32–0.91). The surface under the cumulative ranking curve (SUCRA) suggested that T-DM1LC (91.9%) was ranked first in achieving pCR, followed by the PTC_T-DM1P (90.5%), PTC (74.8%), and T-DM1PC (73.5%) regimens. For SAEs,
Cancers, 2022, 14, 523

LTC, LC, and T-DM1LC presented with the highest risks (SUCRA = 10.7%, 16.8%, and 20.8%), while PT (99.2%), T-DM1P (88%), and T-DM1 (83.9%) were the safest regimens. The T-DM1PC (73.5% vs. 71.6%), T-DM1 (70.5% vs. 83.9%), and PTC_T-DM1P (90.5% vs. 47.3%) regimens offered the optimal balance between pCR and SAE. Conclusions: The T-DM1PC, T-DM1, and PTC_T-DM1P regimens had the optimal balance between efficacy and safety, while DFS was highest for the PTC regimen. However, these results were based on a small number of studies, and additional RCTs assessing the efficacy of regimens with T-DM1 are still needed to confirm these findings.

**Keywords:** targeted therapy; HER2-positive breast cancer; neoadjuvant therapy; systematic review; network meta-analysis

1. Introduction

Breast cancer is the most common cancer among women worldwide, with 2.26 million new cases in 2020. It ranked fifth as the leading cause of mortality and accounted for 15% of cancer deaths in women [1]. Patients with human epidermal growth factor receptor 2 (HER2) positivity, accounting for approximately 20 to 24% of breast cancer patients globally, had more aggressive progression and poorer outcomes than those who were HER2-negative. There have been many recent advances in HER2-targeted therapies, including trastuzumab (T), lapatinib (L), pertuzumab (P), and trastuzumab emtansine (T-DM1), which have significantly improved the progression and overall survival outcomes for HER2+ve breast cancer patients [2,3].

In addition, HER2-targeted therapies have been used as neoadjuvant systemic therapy (i.e., regimen started before surgery) with the aim of improving operability and the pathological complete response (pCR) in early-stage or locally advanced breast cancers [3–5]. Many regimens, including (1) a combination of single HER2-targeted agent with chemotherapy (C) (i.e., trastuzumab + chemotherapy (TC), pertuzumab + chemotherapy (PC), lapatinib + chemotherapy (LC)), (2) dual HER2-targeted agents with chemotherapy (i.e., pertuzumab + trastuzumab + chemotherapy (PTC), lapatinib + trastuzumab + chemotherapy (LTC)), or (3) dual HER2-targeted agents without chemotherapy (i.e., pertuzumab + trastuzumab (PT), trastuzumab emtansine + pertuzumab (T-DM1P)) have been used as neoadjuvant systemic therapies for early-stage or locally advanced breast cancers. The European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) guidelines have recommended trastuzumab as standard neoadjuvant therapy for HER2+ve breast cancer and trastuzumab combined with pertuzumab for high-risk patients with node positivity and/or estrogen receptor negativity [6,7]. However, given the availability of several regimens with limited head-to-head comparisons from randomized controlled trials (RCTs), the identification of the optimal regimen of neoadjuvant with HER2-targeted therapy for HER2+ve breast cancers remains challenging.

Network meta-analysis (NMA) is a method that combines data from direct comparisons to indirectly compare between different interventions by borrowing information from common comparators. In addition, NMA can estimate the probability associated with being the optimal treatment and enables the ranking of both positive and negative effects. Two NMAs published in 2018 and 2019 [8,9] identified the PTC regimen as the best treatment for pCR, whereas T-DM1P was the safest regimen with the lowest probability associated with adverse events. More recently, several RCTs have assessed newer neoadjuvant anti-HER2 regimens (i.e., T-DM1 alone, T-DM1 + lapatinib + chemotherapy (T-DM1LC), T-DM1 + pertuzumab + chemotherapy (T-DM1PC), and PTC +T-DM1P combination regimens) [10,11]. Furthermore, additional patient-relevant outcomes, such as disease-free survival (DFS), were not previously considered in the prior NMAs due to insufficient data. Therefore, this systematic review and NMA aimed to identify the current regimens of neoadjuvant anti-HER2 therapy with the highest probability of DFS and pCR coupled with the lowest risk of adverse events.
2. Materials and Methods

This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the review protocol was registered at the PROSPERO website (CRD42020211532).

2.1. Literature Search and Selection of Studies

Relevant studies were searched in Medline via PubMed, Scopus, and Cochrane Central Register of Controlled Trials from their inceptions to November 2021. Details of search terms and search strategies for each database are provided in Appendix A (see Tables A1–A3).

2.1.1. Selection of Studies

Studies were selected by two independent reviewers (A.D.M.G. and N.T.H.). Randomized controlled trials were eligible if they (1) included early-stage and/or locally advanced HER2+ve breast cancer patients, (2) compared any neoadjuvant regimens that included anti-HER2 therapies, with or without chemotherapy, and (3) reported any of the following outcomes: pCR, DFS, or overall survival. Trials that included HER2+ve breast cancer with distant metastasis or compared the different doses of the same treatment regimen were excluded.

2.1.2. Interventions of Interest

Interventions of interest included neoadjuvant therapies of HER2-targeted agents with or without chemotherapy, such as:

1. Single HER2-targeted agents with chemotherapy (i.e., TC, PC, LC);
2. Dual HER2-targeted agents with chemotherapy (i.e., PTC, LTC, T-DM1PC, T-DM1LC, PTC_T-DM1P). T-DM1PC was a response guided regimen where T-DM1P was provided in cycles 1 through 4, followed by 4 cycles of chemotherapy in non-responders or a continuation of 2 cycles of T-DM1P in responders. PTC_T-DM1P was a regimen where PTC was provided in cycles 1 through 4, followed by T-DM1P in cycles 5 through 8;
3. Dual HER2-targeted agents without chemotherapy (i.e., PT, T-DM1P);
4. Single HER2-targeted agents without chemotherapy (i.e., T-DM1);

Comparators were chemotherapy alone or different regimens of neoadjuvant anti-HER2 agents.

2.1.3. Outcomes of Interest

Primary outcomes of interest were DFS, overall survival, and pCR. DFS was defined as the time from randomization to first locoregional recurrence, contralateral breast cancer or distant metastasis or death from any cause [12]. Although overall survival was defined as the time from randomization to death from any cause [12,13], the limited number of studies reporting this outcome prevented its evaluation. Pathological complete response was defined as no histological evidence of residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/Tis and ypN0) [5,14].

The secondary outcomes were (1) serious adverse events (SAE), which included grades 3–4 adverse events (i.e., life threatening events, events requiring hospitalization) according to National Cancer Institute Common Terminology Criteria (NCICTC) [15], and (2) breast conservation surgery (BCS) as the final surgical procedure.

2.2. Data Extraction

Data were extracted by two independent reviewers (A.D.M.G., N.T.H.), including study characteristics (i.e., setting, follow-up time, participant numbers), patient characteristics (i.e., mean age, cancer stage, tumor size, nodal status, hormone receptor status, body mass index (BMI), family history of breast cancer, breast feeding, menopausal status), intervention characteristics (i.e., treatment regimens, dosages, course), and types of outcomes. For data pooling, contingency data between treatments and outcomes were extracted. For
DFS, time (on x-axis), probability of outcome occurrence (on y-axis), number of events, and person-time at risk at each time point were extracted from Kaplan–Meier (KM) curves using webplot digitizer software [16].

2.3. Risk of Bias Assessment

Risk of bias of each study was assessed using the revised Cochrane risk-of-bias tool (RoB 2) by one reviewer (A.D.M.G.) and randomly checked by senior author (T.A.) [17,18]. Five domains (i.e., randomization, protocol deviation, missing outcome data, measurement of outcome, selection of results reported) were assessed and ranked as low risk, some concern, and high risk. An overall ROB was further classified as low, some concern, and high risk of bias; if all five domains were ranked as low risk, at least one domain was ranked as some concern without high risk, and at least one domain was ranked as high risk, respectively.

2.4. Statistical Analysis

Direct meta-analysis was performed if two or more studies with similar treatment comparisons and outcomes were available. Risk ratios (RR) of pCR, BCS, and SAEs were estimated and pooled across studies using the inverse variance method (fixed-effects) if there was no heterogeneity; otherwise, the DerSimonian–Laird method (random effects) was applied. Heterogeneity was assessed using Cochran’s Q test and I² statistic. Heterogeneity was present if the p-value from Q-test < 0.10 and/or I² > 25%. Sources of heterogeneity were explored using a meta-regression by fitting co-variables (i.e., node positivity, hormone receptor negativity, chemotherapy regimens (i.e., taxane and taxane + anthracycline) and duration of anti HER2 treatment) one by one. Further subgroup analysis was performed if the Tau² value decreased by more than 50% after fitting the co-variable in the meta-regression model. Publication bias was assessed using Egger’s tests and funnel plots. If there was asymmetry of the funnel plot, a contour-enhanced funnel plot was generated to identify the cause of asymmetry (i.e., small study effect or heterogeneity) [19,20].

The NMAs for pCR, SAE, and BCS were performed using a two-stage NMA approach. First, a relative treatment effect (lnRR) was estimated along with the variance–covariance matrix using a binary regression model. Second, a multivariate meta-analysis with consistency model was applied to pool the lnRRs across studies. Treatment ranking was done using the rankogram and the surface under cumulative ranking curve (SUCRA). Cluster ranking considering both efficacy (pCR) and safety (SAE) was also performed to simultaneously weigh the risks and benefits of each intervention [21,22].

For DFS, the number of events, patients at risk, and probability of DFS at each time point were used to simulate individual patient data IPD for each study [23], and then pooled across all studies. A mixed-effect parametric survival analysis with Weibull distribution was applied to estimate relative treatment effects, i.e., hazard ratio (HR) between different neoadjuvant HER2-targeted regimens [24–27].

A comparison-adjusted funnel plot was constructed to assess publication bias across the network. The consistency assumption was assessed using design-by-treatment interaction inconsistency model [28]. If there was inconsistency (p-value < 0.05), treatment loops having high inconsistency factors (IF) were explored. Subgroup analysis was then performed by excluding studies with different characteristics to improve consistency of the model. All statistical analyses were conducted using STATA program version 16.0. A p-value less than 0.05 was considered statistically significant for all tests except for Cochran’s Q test, for which a p-value less than 0.10 was applied.

3. Results

Of the 3010 studies identified, 32 published studies [5,10–12,29–56], including 21 RCTs [10,11,29,31,32,34,35,38–40,43–51,53,54], were eligible for inclusion within this analysis (Figure 1). Among these, four anti-HER2 medicines (i.e., T, L, P, T-DM1) were evaluated in 11 regimens (i.e., TC, LC, PC, PT, T-DM1P, PTC, LTC, T-DM1LC, T-DM1PC,
PTC_T-DM1P, T-DM1) along with chemotherapy alone (see Table S1). The individual study characteristics are presented in Table 1. Twelve RCTs were comprised of two arms, for which TC vs. C was the most common treatment comparison (5 RCTs) [30,32,34,35,45], followed by TC vs. LC (2 RCTs) [12,46], with the remainder comprising unique comparisons [10,49–51,54]. Eight RCTs included three arms with seven RCTs comparing TC vs. LC vs. LTC [31,40,43,44,47,48,53]; a single RCT compared PTC vs. T-DM1PC vs. PTC_T-DM1P [11], while one trial comprised four arms that compared TC vs. PC vs. PT vs. PTC [38]. The duration of treatment ranged from 12 to 30 weeks with different dosages and cycle lengths (see Table S2). The median age ranged from 48 to 53 years, and nodal positivity ranged from 20% to 80%. Tumor grade was largely T2 and T3, and at least 40% or more of patients were hormone receptor negative (i.e., both estrogen and progesterone receptors negative). All 21 RCTs reported pCR and SAE, while BCS, DFS, and overall survival were reported in 12, 10, and 7 RCTs, respectively. Only 7 and 4 RCTs provided KM curves for DFS and overall survival, respectively, with the latter insufficient for pooling.

**Figure 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
| Study                         | Country | Total Participants | Regimen | Age (Yrs) Median (Range) | Stage of Breast Cancer | Median Size of Tumor (mm) | T Stage | % Nodal Positive | % Hormone Receptor Negative | % Premenopausal | % Withdrawal | % Discontinuation of Treatment | Funding Source                                      |
|------------------------------|---------|-------------------|----------|-------------------------|------------------------|---------------------------|---------|-----------------|-----------------------------|----------------|--------------|--------------------------|-----------------------------------------------|
| Buzdar et al., 2005, Buzdar et al., 2007 | USA     | 42                | C        | 46 (25-75)              | I II III                 | 2 13 4 0                  | 63      | 42              | NR                          | NR             | NR           | NR                       | Genentech, Pfizer, and Bristol Myers Squibb  |
|                              |         |                   | TC       | 52 (26-71)              | I II III                 | 2 15 5 1                  | 57      | 43              | NR                          | NR             | NR           | NR                       |                                               |
|                              |         |                   | TC       | 50 (34-65)              | - 30 6                   | 30                       | -       | 42              | 47                          | 0 (0%)         | 0 (0%)       |                          |                                               |
|                              | Italy   | 121               | LC       | 49 (34-64)              | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       | CIP                                                   |
|                              |         |                   | LTC      | 49 (26-45)              | 15 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        | GS K                                                |
|                               | Italy   | 120               | C        | 58                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          | French Programme Hospitalier de Recherche Clinique, Pfizer Inc, France, Roche Pharmaceutical, and Sanofi-Aventis. |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | France  | 120               | C        | 58                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          | GS K                                                |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | France  | 120               | C        | 58                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          | GS K                                                |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | Canada  | 100               | C        | 55                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          |                                               |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               |         |                   | C        | 55                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          |                                               |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | France  | 120               | C        | 55                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          | GS K                                                |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | France  | 120               | C        | 55                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          | GS K                                                |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | Canada  | 100               | C        | 55                       | -                        | -                        | 27 31 (T3/T4)           | 67      | 36              | -                           | 0 (0%)         | NR           |                          |                                               |
|                               |         |                   | TC       | 62                       | -                        | -                        | 32 30 (T3/T4)           | 60      | 45              | -                           | 0 (0%)         | 5 (8.06%)    |                          |                                               |
|                               |         |                   | LC       | 69                       | 32 23                    | 30                       | -       | -               | 38                          | 39             | 3 (2.56%)     | 12 (30.77%)                       |                                               |
|                               |         |                   | LTC      | 46                       | 13 9                     | 35                       | -       | -               | 39                          | 42             | 2 (2.17%)     | 9 (17.00%)                        |                                               |
|                               | USA     | 529               | C        | 51.1 (21-67)             | -                        | -                        | 22 8 3 45            | 62      | 42              | 0 (0%)                     | 7 (21.21%)      |                          |                          | GS K                                                |
|                               |         |                   | TC       | 51.2 (25-47)             | -                        | -                        | 22 8 3 45            | 62      | 42              | 0 (0%)                     | 7 (21.21%)      |                          |                          |                                               |
|                               |         |                   | LC       | 49.2 (28-66)             | -                        | -                        | 22 8 3 45            | 62      | 42              | 0 (0%)                     | 7 (21.21%)      |                          |                          |                                               |
## Table 1. Cont.

| Study                          | Country          | Total Participants | Regimen No. Per Arm | Age (yrs) Median (Range) | Stage of Breast Cancer | Median Size of Tumor (mm) | T Stage | % Nodal Positive | % Hormone Receptor Negative | % Premenopausal | % Withdrawal | Discontinuation of Treatment | Funding Source                                                                 |
|-------------------------------|------------------|--------------------|---------------------|--------------------------|------------------------|---------------------------|---------|------------------|--------------------------------|------------------|----------------|--------------------------------|-----------------------------------------------------------------------------|
| ABCSG-24 (2014) [13]          | Austria          | 93                 | C 49                | 48 (29–68)               | I II III                | 9 24 15 1                | 51      | 39               | 57                            | NR               | NR            | NR                             | Amgen Austria, Roche Austria, SanofiAventis Austria, and EBEVE Austria       |
| GECAM/2006-14 (2014) [14]     | Spain            | 102                | TC 50               | 48.5 (32–74)             | I II III                | 33 6 31 4 9              | 74      | 21               | 58                            | 0 (0%)            | 2 (4.0%)      | 2 (4.0%)                          | CSK                                                                          |
| GEICAM/2006-14 (2015) [17]    | Spain            | 102                | LC 52               | 46 (26-75)               | I II III                | 8 29 8 7                | 63      | 22               | 34                            | 0 (0%)            | 10 (19.2%)  | 10 (19.2%)                        | US National Cancer Institute, Fonds Cancer (FOCA) Belgium, Cancer Research UK and French Ligue Nationale Contre le Cancer, CSK |
| EORTC 10054 (2015) [13]       | France, Europe   | 128                | TC 23               | 49.9 (27.3–68.9)         | I II III                | 1 11 5 2                | 20      | 26               | 0                             | 4 (4.0%)          | 8 (8.0%)      | 0 (0%)                           | National Cancer Institute (NCI), GSK, and the University of North Carolina |
| CALGB 40601 (2016, 2020)      | USA              | 299                | LTC 117             | 48 (24–70)               | I II III                | 40 - - -                 | 40      | 62               | 1 (0.85%)                        | 26 (22.22%)       |                           |                       | National Cancer Institute (NCI), GSK, and the University of North Carolina |
| WSG-ADAPT (2017) [16]         | Germany          | 134                | PT 92               | 54                        | I II III                | 38 47 6 1                | 46      | 100              | 0                             | 0 (0%)            | 4 (9.52%)     | 0 (0%)                           | Hoffmann-La Roche                                                        |
| KRISTINE (2018, 2019) [9,12]  | International    | 444                | PTC 223             | 50 (42-97)               | I II III                | - - - -                  | -       | -                | 0 (0%)                          | 14 (7.17%)         |                           |                       | Hoffmann-La Roche and Genentech                                          |
| Test study (2019) [11]        | USA              | 30                 | PTC 221             | 49 (43–57)               | I II III                | - - - -                  | -       | -                | 0 (0%)                          | 0 (0%)            | 8 (2.62%)     | 0 (0%)                           | Colgave and Novartis                                                      |
| PEONY (2009) [10]             | China            | 329                | T-DM1P 221           | 50 (42-67)               | I II III                | - - - -                  | -       | -                | 0 (0%)                          | 8 (3.62%)          |                           |                       | Hoffmann-La Roche                                                          |
| Masuda et al., 2020 [1]       | Japan            | 204                | PTC 95              | 55 (28-63)               | I II III                | - - - -                  | -       | -                | 0 (0%)                          | 0 (0%)            | 5 (2.52%)     | 0 (0%)                           | Japan Breast Cancer Research Group (JBCRG). Chugai Pharmaceutical Co., Ltd. |
| TRIO-US R07 (2020) [15]       | USA              | 128                | TC 34               | 48 (20–62)               | I II III                | 27 102 9                | 40      | 0 (0%)           | 0 (0%)                          | 0 (0%)            | 10 (7.98%)    | 0 (0%)                           | SanofiAventis and GSK                                                     |
| Hatchev et al., 2021 [14]     | Sweden           | 198                | T-DM1 99            | 53 (29–68)               | I II III                | 20 41 17                | 50.5    | 40               | 4.8 (9.09%)                     | 17 (8.70%)         |                           |                       | Region Stockholm, Karolinska Institut, Swedish Cancer Society, Roche Sweden |

C = Chemotherapy; TC = Trastuzumab + chemotherapy; PC = Pertuzumab + chemotherapy; LC = Lapatinib + che-motherapy; PT = Pertuzumab + trastuzumab + chemotherapy; LTC = Lapatinib + trastuzumab + chemotherapy; PT = Pertuzumab + trastuzumab + chemotherapy; T-DM1 = trastuzumab emtansine; T-DM1P = trastuzumab emtansine + pertuzumab; T-DM1LC = trastuzumab emtansine + lapatinib + chemotherapy; T-DM1PC = trastuzumab emtansine + pertuzumab + chemotherapy; PTC T-DM1 = pertuzumab + trastuzumab + chemotherapy followed by trastuzumab emtansine + pertuzumab.
3.1. Risk of Bias Assessment

The results of the risk of bias assessment for the pCR, BCS, DFS, and SAE outcomes are presented in Table S3. The majority of the studies for pCR (13/21), BCS (9/12), and DFS (4/7) had a low risk of bias, and none had a high risk of bias. For the SAE outcome, only a single study had an overall high risk of bias due to missing outcome data, with 12 studies registering some concerns.

3.2. Pathological Complete Response

3.2.1. Pairwise Meta-Analysis

The pathological complete response was reported in 21 studies; four treatment comparisons (i.e., TC vs. C, LC vs. TC, LTC vs. TC, and LTC vs. LC) were pooled, indicating significantly higher pCR in TC vs. C [29,33–35,45], LTC vs. TC [31,40,43,44,47,48,53], and LTC vs. LC [31,40,43,44,47,48,53], with corresponding pooled RRs (95% CI) of 1.81 (1.36, 2.42; I^2 = 0%), 1.26 (1.11, 1.42; I^2 = 1.8%), and 1.66 (1.33, 2.06; I^2 = 42%) (see Figure S1A–C). Conversely, LC showed significantly lower pCR than TC, with a pooled RR (95% CI) of 0.74 (0.63, 0.87); I^2 = 26%) [31,39,40,43,44–48,53] (see Figure S1D).

Given the high I^2 value observed in the LTC vs. LC comparison, sources of heterogeneity were explored (see Table S4A). Accounting for types of chemotherapy that decreased the I^2 value from 42% to 0%, a subgroup analysis showed that RR was higher with taxane only than taxane plus anthracycline, with pooled RRs (95% CI) of 2.13 (1.65, 2.75) and 1.33 (1.12, 1.58), respectively (see Figure S2). There was no significant variation in the comparisons from other subgroup analyses (Table S5). For LC vs. TC (see Table S4B), subgroup analyses showed reductions in heterogeneity when accounting for age, percentages of nodal positive, and T3 and T4, although none reached significance (Table S6).

Egger’s tests did not provide any evidence of publication bias for any pCR pooled estimates (see Figure S3), in support of the funnel plots, with the exception for the comparison between TC vs. C, which was asymmetrical (see Figure S3A). A contour-enhanced funnel plot suggested the asymmetry may be a consequence of a small study effect (Figure S3B).

3.2.2. Network Meta-Analysis

The NMA for pCR included 21 studies with 16 comparisons (Figure 2A) and showed consistency (global test chi-square = 2.01, p-value = 0.571). The data used for pooling are described in Table S7. All anti-HER2 regimens except PC, LC, and PT significantly increased pCR when compared to chemotherapy alone, with RRs (95% CI) of 4.03 (2.22, 7.30) for PTC_T-DM1P, 3.25 (1.80, 5.88) for T-DM1PC, 4.42 (2.25, 8.67) for T-DM1LC, 2.24 (1.58, 3.18) for LTC, 3.22 (2.04, 5.09) for PTC, 2.57 (1.48, 4.45) for T-DM1P, 3.08 (1.68, 5.62) for T-DM1, and 1.81 (1.32, 2.48) for TC (see Table 2). Both LC and PT regimens had significantly lower pCR when compared to TC. All dual anti-HER-2 agents plus chemotherapy (i.e., PTC, LTC, T-DM1LC, T-DM1PC, and PTC_T-DM1P) had significantly higher pCR than single anti-HER-2 agents plus chemotherapy regimens (i.e., LC, PC, TC) except LTC vs. PC, with pooled RRs (95% CI) of 1.78 (1.28, 2.48) for PTC vs. TC, 2.44 (1.34, 4.43) for T-DM1LC vs. TC, 2.22 (1.34, 3.68) for PTC_T-DM1P vs. TC, 1.79 (1.09, 2.97) for T-DM1PC vs. TC, and 1.23 (1.06, 1.44) for LTC vs. TC. When compared to PC, pooled RRs were 2.14 (1.27, 3.61) for PTC, 2.93 (1.42, 6.03) for T-DM1LC, 2.67 (1.40, 5.11) for PTC_T-DM1P, 2.16 (1.13, 4.12) for T-DM1PC, and, when compared to LC, pooled RRs were 2.41 (1.66, 3.48) for PTC, 1.67 (1.40, 1.99) for LTC, 3.30 (1.78, 6.13) for T-DM1LC, 2.43 (1.43, 4.12) for T-DM1PC, and 3.01 (1.77, 5.12) for PTC_T-DM1P (see Table 2). T-DM1 also had significantly higher pCR compared to LC, PC, and TC (see Table 2). In addition, all dual anti-HER-2 agents plus chemotherapy regimens T-DM1P and T-DM1 also significantly increased pCR when compared to PT (see Table 2). However, the chance of having pCR with dual anti-HER-2 agents plus chemotherapy regimens did not significantly differ from T-DM1P and T-DM1 regimens. In addition, both T-DM1LC and PTC_T-DM1P had significantly higher pCR compared to LTC, with RRs (95% CI) of 1.97 (1.06, 3.66) and 1.80 (1.06, 3.05), respectively. A SUCRA plot identified T-DM1LC with the highest probability of being the best regimen...
(91.9%), followed by PTC_T-DM1P (90.5%) and PTC (74.8%) (see Figure S4). Adjusted funnel plots were symmetrical, indicating no publication bias (see Figure S5).

Figure 2. Network maps for (A) pathological complete response (pCR), (B) serious adverse events (SAE), and (C) breast conservation surgery (BCS). Nodes and lines represent interventions and direct treatment comparisons with weighted size according to the number of studies for each direct comparison. The numbers on the lines indicate the number of studies for each treatment comparison. C = chemotherapy; TC = Trastuzumab + chemotherapy; PC = Pertuzumab + chemotherapy; LC = Lapatinib + chemotherapy; PTC = Pertuzumab + trastuzumab + chemotherapy; LTC = Lapatinib + trastuzumab + chemotherapy; PT = Pertuzumab + trastuzumab; T-DM1P = trastuzumab emtansine + pertuzumab; T-DM1LC = trastuzumab emtansine + lapatinib + chemotherapy; T-DM1PC = trastuzumab emtansine + pertuzumab + chemotherapy; PTC_T-DM1P = pertuzumab + trastuzumab + chemotherapy followed by trastuzumab emtansine + pertuzumab; T-DM1 = Trastuzumab emtansine.
### Table 2. Risk ratios and 95% confidence intervals of network meta-analysis of pathological complete response (above grey diagonal line) and serious adverse drug events (below grey diagonal line).

|                  | Chemotherapy (C) | Trastuzumab + chemotherapy (TC) | Pertuzumab + chemotherapy (PC) | Lapatinib + chemotherapy (LC) | Pertuzumab + trastuzumab + chemotherapy (PTC) | Pertuzumab + trastuzumab + trastuzumab emtansine + chemotherapy (PTC) | Pertuzumab + trastuzumab + trastuzumab emtansine + pertuzumab (PTC) | Pertuzumab + trastuzumab + trastuzumab emtansine + pertuzumab + chemotherapy (PTC_T-DM1P) | Trastuzumab emtansine (T-DM1) |
|------------------|------------------|---------------------------------|---------------------------------|-------------------------------|-----------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------|
| **Risk Ratio (95% Confidence Intervals)** | 1.81 (1.32, 2.48) | 1.51 (0.79, 2.87) | 1.34 (0.94, 1.91) | 1.10 (0.65, 1.92) | 1.08 (0.79, 1.48) | 0.83 (0.47, 1.46) | 0.74 (0.63, 0.87) | 0.61 (0.39, 0.96) | 1.42 (0.90, 2.22) |
|                  | 2.57 (1.48, 4.45) | 3.22 (2.04, 5.09) | 2.24 (1.58, 3.18) | 4.42 (2.25, 8.67) | 3.17 (1.09, 9.27) | 2.22 (1.34, 3.68) | 1.23 (1.06, 1.44) | 2.44 (1.34, 4.43) | 2.16 (1.13, 4.12) |
|                  | 1.34 (0.94, 1.91) | 1.11 (0.65, 1.92) | 1.34 (0.94, 1.91) | 1.11 (0.65, 1.92) | 1.11 (0.65, 1.92) | 1.08 (0.79, 1.48) | 1.08 (0.79, 1.48) | 1.08 (0.79, 1.48) | 1.08 (0.79, 1.48) |
|                  | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) | 1.26 (0.73, 2.17) |
|                  | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) | 0.83 (0.52, 1.33) |
|                  | 1.92 (1.19, 3.10) | 2.41 (1.66, 3.48) | 1.67 (1.40, 1.99) | 3.30 (1.78, 6.13) | 2.43 (1.43, 4.12) | 3.01 (1.77, 5.12) | 2.76 (1.45, 5.34) | 2.76 (1.45, 5.34) | 2.76 (1.45, 5.34) |
|                  | 3.13 (2.46, 3.96) | 4.41 (3.02, 6.52) | 3.04 (2.11, 4.39) | 7.90 (5.35, 11.99) | 4.44 (2.54, 7.70) | 3.50 (2.17, 5.62) | 2.76 (1.65, 4.61) | 2.76 (1.65, 4.61) | 2.76 (1.65, 4.61) |
|                  | 4.03 (2.22, 7.30) | 3.08 (1.68, 5.62) | 2.57 (1.48, 4.45) | 4.42 (2.25, 8.67) | 3.17 (1.09, 9.27) | 2.22 (1.34, 3.68) | 1.23 (1.06, 1.44) | 2.44 (1.34, 4.43) | 2.16 (1.13, 4.12) |
| **PT**           | 2.31 (1.47, 3.61) | 2.89 (2.08, 4.01) | 2.01 (1.26, 3.21) | 3.96 (2.18, 7.19) | 2.92 (1.77, 4.82) | 3.62 (2.19, 5.98) | 2.76 (1.45, 5.34) | 2.76 (1.45, 5.34) | 2.76 (1.45, 5.34) |
| **PDC**          | 1.70 (0.93, 3.12) | 1.48 (0.83, 2.66) | 2.93 (1.42, 6.03) | 2.16 (1.13, 4.12) | 2.67 (1.40, 5.11) | 2.04 (1.06, 3.93) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) |
| **LC**           | 1.70 (0.93, 3.12) | 1.48 (0.83, 2.66) | 2.93 (1.42, 6.03) | 2.16 (1.13, 4.12) | 2.67 (1.40, 5.11) | 2.04 (1.06, 3.93) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) |
| **PC**           | 1.70 (0.93, 3.12) | 1.48 (0.83, 2.66) | 2.93 (1.42, 6.03) | 2.16 (1.13, 4.12) | 2.67 (1.40, 5.11) | 2.04 (1.06, 3.93) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) |
| **TC**           | 1.70 (0.93, 3.12) | 1.48 (0.83, 2.66) | 2.93 (1.42, 6.03) | 2.16 (1.13, 4.12) | 2.67 (1.40, 5.11) | 2.04 (1.06, 3.93) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) | 2.57 (1.48, 4.45) |

Results of treatment comparisons are read from right to left. For example, the risk ratio (95% confidence intervals) for pCR of TC vs. C is 1.81 (1.32, 2.48) and the risk ratio (95% confidence intervals) for SAE of TC vs. C is 1.08 (0.79, 1.48). Bold font indicates significance. C = Chemotherapy; TC = Trastuzumab + chemotherapy; PC = Pertuzumab + chemotherapy; LC = Lapatinib + chemotherapy; PTC = Pertuzumab + trastuzumab + chemotherapy; PTC_T-DM1P = Pertuzumab + trastuzumab + chemotherapy followed by trastuzumab emtansine + Pertuzumab + chemotherapy. T-DM1 = Trastuzumab emtansine.
3.3. Serious Adverse Events

Twenty-one studies reported grade 3 and 4 adverse events that were included in the analysis of SAE [10,31,32,35,40,45–48,53,54].

3.3.1. Pairwise Meta-Analysis

Of the 21 studies, treatment comparisons included TC vs. C (five studies), LC vs. TC (nine studies), LTC vs. TC (seven studies), and LTC vs. LC (seven studies). The SAEs were not significantly different for TC vs. C and LTC vs. LC (see Figure S6A,B), whereas LC and LTC had significantly higher SAEs than TC with pooled RRs (95% CI) of 1.43 (1.08, 1.89; $I^2 = 79.97\%$) and 1.77 (1.22, 2.59; $I^2 = 73.78\%$), respectively (Figure S6C,D).

The type of chemotherapy included could reduce the level of heterogeneity ($\tau^2$) for both LC vs. TC and LTC vs. TC, respectively (Table S8A,B). The subgroup analyses indicated that risks of SAEs in LC and LTC were higher than TC for the taxane regimen alone compared to taxane plus anthracycline regimens (Figure S7A,B).

There was no evidence of publication bias as indicated by either Egger’s tests or funnel plots for TC vs. C and LTC vs. LC (Figure S8A,F). The funnel plots for LC vs. TC and LTC vs. TC were asymmetrical (Figure S8B,D), which may be due to heterogeneity, as suggested from the contour-enhanced funnel plots (Figure S8C,E).

3.3.2. Network Meta-Analysis

Data used for NMA of SAE are described in Table S9. A global test ($\chi^2 = 7.87$, p-value = 0.049) suggested evidence of inconsistency across the 21 studies considered. An inconsistency factor (IF) plot identified the TC-PT-PTC loop with the highest IF (1.90, 95% CI: 0.31, 3.48) (Figure S9). Study characteristics in this loop were explored (see Table S10), and the trial by Nitz et al. [49] included only hormonal receptor negative breast cancers. After removing this study, the network was deemed consistent (chi-square = 3.24, p-value = 0.198) (see Figure 2B). Relative treatment effects were estimated, indicating that single and dual anti-HER2 regimens without chemotherapy (i.e., T-DM1, PT, T-DM1P) had significantly lower SAE risk compared to single anti-HER2 agents with chemotherapy (i.e., TC, PC, LC) (see Table 2). All dual anti-HER2 agents with chemotherapy (i.e., PT, LTC, T-DM1LC, T-DM1PC, and PTC_T-DM1P) also had significantly higher SAE risk compared to dual anti-HER2 regimens without chemotherapy (i.e., PT and T-DM1P), with pooled RRs (95% CI) of 6.72 (2.06, 21.89) for T-DM1PC vs. PT, 12.14 (3.77,39.07) for PTC_T-DM1P vs. PT, and 4.48 (2.12,9.47) for T-DM1PC vs. T-DM1P, respectively. The SAE risk in the T-DM1 regimen was not significantly different compared to dual anti-HER2 regimens without chemotherapy (i.e., PT and T-DM1P) (see Table 2). Among the regimens with chemotherapy, T-DM1PC had a significantly lower risk of SAE than TC, PC, LC, as well as PTC and LTC, with pooled RRs (95% CI) of 0.48 (0.26,0.91), 0.46 (0.23,0.94), 0.37 (0.19, 0.73), 0.50 (0.30, 0.85), and 0.34 (0.17, 0.69), respectively (see Table 2). In addition, the risk of SAE was significantly higher in LTC compared to TC, with a pooled RR of 1.40 (1.04, 1.89). According to SUCRA, PT had the highest probability of having the lowest risk of SAE (99.2%), followed by T-DM1P (88%), T-DM1 (83.9%), and T-DM1PC (71.6%); LTC was associated with the poorest risk of SAE (10.7%) (see Figure S10). The comparison-adjusted funnel plots were symmetrical, suggesting no evidence of publication bias (Figure S11).

3.4. Ranking of Regimens According to Efficacy and Safety

A cluster rank plot was constructed considering the SUCRA of pCR on the x-axis and SUCRA of lowering SAEs on the y-axis (Figure 3). T-DM1LC was located in the bottom right of the graph, representing the highest pCR with high SAEs, while T-DM1PC, PTC, T-DM1, and PTC_T-DM1P still ranked high for pCR but had better SAE profiles. Therefore, T-DM1PC, T-DM1, PTC, and PTC_T-DM1P provided an optimal balance between efficacy and risk of SAE.
3.5. Breast Conservation Surgery

BCS was reported in 12 of the 21 studies [11,29,31,36,38,40,41,43,45,47,50,54].

3.5.1. Pairwise Meta-Analysis

Four treatment comparisons (i.e., TC vs. C (three studies) [30,36,45], LC vs. TC (five studies) [31,41,43,46,47], LTC vs. TC (four studies) [31,41,43,47], and LTC vs. LC (four studies) [31,41,43,47]) had sufficient data for pooling. None of these studies showed significant differences of BCS between treatment comparisons, with corresponding pooled RRs (95% CI) of 1.10 (0.73, 1.64; $I^2 = 53.01\%$) for TC vs. C, 0.97 (0.83, 1.14; $I^2 = 25.34\%$) for LC vs. TC, 1.00 (0.87, 1.14; $I^2 = 0\%$) for LTC vs. TC, and 1.05 (0.91, 1.21; $I^2 = 0\%$) for LTC vs. LC (Figure S12A–D).

3.5.2. Network Meta-Analysis

The NMA included 12 studies with 11 treatment regimens that passed the consistency assumption (global test chi-square = 0.16, p-value = 0.6937) (see Figure 2C). There were no significant differences in BCS for any of the treatment comparisons except for PTC vs. T-DM1P, with a pooled RR (95% CI) of 1.26 (1.02, 1.55) (see Table S11). PTC (68.5%) was ranked best in terms of having the highest BCS (Figure S13). The comparison-adjusted funnel plots were symmetrical and indicated no evidence of publication bias (Figure S14).

3.6. Disease-Free Survival

Of the 21 RCTs, 10 reported DFS [5,11,12,30,33,37,42,52,54,56], but only seven studies [5,12,37,42,52,54,56] provided KM curves from which IPD could be simulated. The
follow-up time ranged from 36 to 168 months, with a median of 48 months. The regimens included were C, TC, PC, LC, PT, PTC, LTC, T-DM1P, and T-DM1. The mixed-effect parametric survival analysis identified PTC with the highest DFS, in contrast to C, which had the lowest DFS (see Figure 4). Compared to TC, chemotherapy alone had a significantly higher risk of disease recurrence (HR = 1.70 95% CI: 1.15–2.51), while PTC had a significantly lower risk of disease recurrence with an HR (95% CI) of 0.54 (0.32–0.91). Disease recurrence in PC, LC, PT, LTC, T-DM1P, and T-DM1 did not differ significantly from TC (see Table 3).

Figure 4. Mixed-effect parametric survival analysis of disease-free survival. C = chemotherapy; TC = Trastuzumab + chemotherapy; PC = Pertuzumab + chemotherapy; LC = Lapatinib + chemotherapy; PTC = Pertuzumab + trastuzumab + chemotherapy; LTC = Lapatinib + trastuzumab + chemotherapy; PT = Pertuzumab + trastuzumab; T-DM1P = trastuzumab emtansine + pertuzumab; T-DM1 = Trastuzumab emtansine.

Table 3. Hazard ratios of disease-free survival of neoadjuvant regimens.

| Treatment Regimen | Predicted Median DFS (Months) | Hazard Ratio | 95% Confidence Interval | p-Value |
|------------------|-------------------------------|--------------|------------------------|---------|
| TC               | 173.23                        | 1            | -                      | -       |
| C                | 100.92                        | 1.70         | 1.15–2.51              | 0.008   |
| PC               | 128.67                        | 1.34         | 0.78–2.29              | 0.291   |
| LC               | 155.27                        | 1.11         | 0.87–1.43              | 0.403   |
| PT               | 124.69                        | 1.38         | 0.82–2.33              | 0.228   |
| PTC              | 327.84                        | 0.54         | 0.32–0.91              | 0.02    |
| LTC              | 203.96                        | 0.85         | 0.60–1.22              | 0.378   |
| T-DM1P           | 144.18                        | 1.20         | 0.61–2.33              | 0.598   |
| T-DM1            | 243.35                        | 0.72         | 0.30–1.72              | 0.457   |

C = Chemotherapy; TC = Trastuzumab + chemotherapy; PC = Pertuzumab + chemotherapy; LC = Lapatinib + chemotherapy; PTC = Pertuzumab + trastuzumab + chemotherapy; LTC = Lapatinib + trastuzumab + chemotherapy; PT = Pertuzumab + trastuzumab; T-DM1P = trastuzumab emtansine + pertuzumab; T-DM1 = Trastuzumab emtansine.
4. Discussion

Our results suggest that T-DM1LC has the highest probability of achieving pCR, followed by PTC_T-DM1P and PTC, respectively. In addition, PTC also provided the longest DFS. PT was ranked first (i.e., lowest risk) for SAE, followed by T-DM1P and T-DM1. When considering both the optimal benefit (pCR or DFS) and risk (SAE) together, T-DM1PC, PTC_T-DM1P, T-DM1, or PTC were considered the best regimens for neoadjuvant anti-HER2 therapy.

Previous NMAs by Wu et al. [9] and Nakashoji et al. [8] identified PTC as the best neoadjuvant anti-HER2 regimen for achieving pCR in early-stage breast cancer. With our updated data, T-DM1LC now represents the top-ranked treatment, with PTC dropping to the third-ranked treatment in terms of pCR outcomes. In this fast-moving field of cancer therapeutics, the more recently available regimens of T-DM1 were not considered within the previous NMAs, including T-DM1, T-DM1LC, T-DM1PC, and PTC_T-DM1P. Trastuzumab emtansine consists of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine), which can directly deliver cytotoxic molecules to tumors, potentially increasing the efficacy in comparison to trastuzumab [57,58]. Beyond pCR outcomes, our study also assessed the efficacy of neoadjuvant anti-HER2 therapies to prolong DFS, an outcome not considered in previous NMAs. PTC significantly increased DFS compared to TC, while none of the other anti-HER2 regimens significantly differed from TC. Nevertheless, there were some limitations associated with the more recent T-DM1 regimens, such as T-DM1 and T-DM1P, which had insufficient data to properly evaluate this outcome.

Although T-DM1LC was ranked the best for the pCR outcome, its SAE rate was very high. This may be due to lapatinib, which is associated with a higher risk of SAE grades 3–4, such as neutropenia, diarrhea, and hepatotoxicity [31,40,43,59]. Our study also indicated that all the regimens containing lapatinib (i.e., LTC, LC, and T-DM1LC) were ranked the worst for SAE. In addition to lapatinib, SAE grades 3–4 were commonly found in regimens with chemotherapy. Three regimens without chemotherapy (i.e., PT, T-DM1, and T-DM1P) were the best treatments for lowering SAEs. However, the efficacy of PT in terms of pCR and DFS was very low in comparison to the other regimens.

Moreover, the percentage of patients who discontinued the treatment was high in regimens with lapatinib. However, most studies applied intention to treat analysis for analyzing the data. Although this analysis might underestimate the true treatment efficacy in the ideal situation, it usually reflects the efficacy of the drugs when using them in the real-clinical setting where some patients may not be complying well with the treatment regimen.

When considering the benefit (pCR) and risk (SAE) together, T-DM1PC and T-DM1 were identified as the optimal neoadjuvant therapy for early-stage HER2+ve breast cancer given the greater chance of achieving pCR and the low risk of SAE. PTC_T-DM1P was identified as the next-best alternative regimen given the higher pCR to T-DM1PC coupled with the greater risk of SAE compared to T-DM1PC. These conclusions contrast to those from previous NMAs, which indicated PTC as the most effective treatment. However, our NMA has been updated to include the most recent treatment regimens and confirms that switching trastuzumab to T-DM1 in combination with PC could offer increased efficacy coupled with decreased risk of SAE. In addition, our findings failed to support chemotherapy alone or single anti-HER2 regimens in combination with chemotherapy (i.e., TC, PC, LC) as optimal neoadjuvant therapies for the treatment of early-stage HER2+ve breast cancer due to a very low chance of achieving pCR and an associated increased risk of SAE.

Although the recommended regimens of T-DM1 were top-ranked in our cluster ranking plot, its prohibitively high cost of $127,035 USD per patient per year should be considered [60]. Therefore, affordability and accessibility may be issues, especially in low- and middle-income countries, warranting economic evaluation before further consideration of these regimens.
Strengths and Limitations

To our knowledge, our NMA is the most up to date, and includes novel neoadjuvant anti-HER2 regimens with combinations of T-DM1 and chemotherapy, providing the most current evidence for treatment recommendations for HER2+ve breast cancer. Moreover, DFS is a clinically important outcome measure not considered in previous NMAs. However, not all novel regimens provided sufficient DFS outcome data for pooling, especially those regimens that included T-DM1. Therefore, we were unable to compare the regimen efficacy for DFS outcomes between new neoadjuvant anti-HER2 regimens, including T-DM1 and PTC, with other regimens, and, as such, recommendations on the optimal treatment regimens were mainly based on the outcomes of pCR and SAE. Nevertheless, several RCTs and meta-analyses suggest pCR following neoadjuvant therapy in HER2+ve breast cancer is a valid surrogate of long-term outcomes [61–63].

Our study also had some limitations. First, there were a small number of studies and participants that included newer treatment regimens, such as T-DM1 (i.e., T-DM1PC, T-DM1LC, PTC_T-DM1P, and T-DM1). We pooled the treatment effects based on a small number of included studies, each of which also had small sample sizes, which might result in the imprecision or uncertainty of treatment effects estimated from the network meta-analysis. Therefore, additional RCTs are needed to substantiate the findings from our study. Second, due to insufficient data, we were unable to analyze overall survival outcomes, which is the most important outcome of cancer treatment. Nevertheless, it has been shown that DFS is an adequate proxy for overall survival in HER2+ve breast cancer patients [64]. Third, all the included studies were funded by the pharmaceutical companies, which might have influenced the study, data analysis, or reporting the results. Therefore, further updated pooling treatment effects are required when there are more studies with new treatment regimens and/or with non-profit sponsors.

5. Conclusions

In conclusion, the T-DM1PC, T-DM1, and PTC_T-DM1P regimens had the optimal balance between efficacy (pCR) and safety (SAE) compared to other neoadjuvant anti-HER2 regimens for early-stage and locally advanced HER2+ve breast cancer, while DFS was the highest for the PTC regimen. Nonetheless, the results of regimens with T-DM1 are based on a small number of studies. Thus, additional RCTs to assess the efficacy of neoadjuvant regimens with T-DM1 are still needed to confirm these findings.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers14030523/s1, Figure S1: Forest plots of pairwise meta-analyses for pathological complete response (pCR), Figure S2: Subgroup analysis of pathological complete response (pCR) in LTC vs. LC according to types of chemotherapy, Figure S3: Funnel plots and contour-enhanced funnel plots of pairwise meta-analyses comparisons for pathological complete response (pCR), Figure S4: Surface under the cumulative ranking curves (SUCRA) for pathological complete response (pCR), Figure S5: Comparison-adjusted funnel plot of network meta-analysis of pathological complete response (pCR), Figure S6: Forest plots of pairwise meta-analyses for serious adverse events (SAE), Figure S7: Subgroup analyses according to types of chemotherapy for serious adverse events (SAE) (a) LC vs. TC; (b) LTC vs. TC, Figure S8: Funnel plots and contour-enhanced funnel plots of pairwise meta-analyses for serious adverse events (SAE), Figure S9: Inconsistency factor plot in network meta-analysis for serious adverse events (SAE), Figure S10: Surface under the cumulative ranking curves (SUCRA) for serious adverse events (SAE), Figure S11: Comparison-adjusted funnel plot of network meta-analysis for serious adverse events (SAE), Figure S12: Forest plots of pairwise meta-analyses for total breast conservation surgery, Figure S13: Surface under the cumulative ranking curves (SUCRA) of total breast conservation surgery (BCS), Figure S14: Comparison-adjusted funnel plot of network meta-analysis for total breast conservation surgery (BCS), Table S1: Summary of studies and total number of patients included for each treatment regimen, Table S2: Details of study’s interventions, Table S3: Results of risk of bias assessment, Table S4: Results of meta regression of LTC vs. LC and LC vs. TC for pathologic complete response (pCR) outcome, Table S5: Subgroup analyses of LTC vs. LC for pathological complete response (pCR) outcome, Table S6: Subgroup analyses of LC
vs. TC for pathological complete response (pCR) outcome, Table S7: Treatment comparisons and data used for pooling pathological complete response (pCR) outcome in network meta-analysis, Table S8: Results of meta regression of LC vs. TC and LTC vs. TC comparisons for serious adverse events (SAE) outcome, Table S9: Treatment comparisons and data used for pooling serious adverse events (SAE) outcome in network meta-analysis, Table S10: Comparison of study characteristics in treatment loop with inconsistency for serious adverse events (SAE) outcome, Table S11: Risk ratios and 95% confidence intervals of network meta-analysis of total breast conservative surgery (BCS) outcome. References [11,29,30,34,38,49,51,54] are cited in the supplementary materials.

**Author Contributions:** Conceptualization, A.D.M.G., T.A., S.Y. and A.T.; methodology, A.D.M.G., T.A., S.Y. and A.T., investigation, A.D.M.G.; data curation, A.D.M.G., N.T.H. and T.A.; formal analysis, A.D.M.G., T.A. and A.T.; writing—original draft preparation, A.D.M.G. and T.A.; writing—review and editing, A.D.M.G., T.A., S.Y., G.J.M., J.A. and A.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Appendix A**

**Search Terms and Search Strategies**

**Table A1.** Search terms and search strategy in Medline.

| Domain | No. | Search Terms |
|--------|-----|--------------|
| P 1    | #1  | “breast cancer” [All Fields] |
|        | #2  | “breast neoplasms” [All Fields] OR “breast neoplasms” [MeSH Terms] |
|        | #3  | #1 OR #2 |
| P 2    | #4  | “human epidermal growth factor receptor 2” [All Fields] |
|        | #5  | “HER2” [All Fields] |
|        | #6  | “ERBB2 protein, human” [All Fields] |
|        | #7  | “erb2-2 genes” [All Fields] |
|        | #8  | #4 OR #5 OR #6 OR #7 |
| P      | #9  | P1 AND P2 AND #3 AND #8 |
| I 1    | #10 | “neoadjuvant” [All Fields] |
|        | #11 | “preoperative” [All Fields] |
|        | #12 | #10 OR #11 |
| I 2    | #13 | “anti HER2” [All Fields] OR “anti human epidermal growth factor receptor 2” [All Fields] |
|        | #14 | “targeted therapy” [All Fields] |
|        | #15 | “trastuzumab” [All Fields] OR “Herceptin” [All Fields] |
|        | #16 | “pertuzumab” [All Fields] |
|        | #17 | “lapatinib” [All Fields] OR “Tykerb” [All Fields] |
|        | #18 | #13 OR #14 OR #15 OR #16 OR #17 |
| I      | #19 | I 1 OR I 2 OR #12 OR #18 |
| O 1    | #20 | “complete response” |
| O 2    | #21 | “disease-free survival” [All Fields] |
|        | #22 | “progression-free survival” [All Fields] |
|        | #23 | “event free survival” [All Fields] |
|        | #24 | “overall survival” [All Fields] |
|        | #25 | “survival” [All Fields] |
|        | #26 | #21 OR #22 OR #23 OR #24 OR #25 |
|        | #27 | “mortality” [All Fields] |
| O 2    | #28 | #26 OR #27 |
| O 3    | #29 | “adverse event” [All Fields] OR “adverse events” [All Fields] |
| O      | #30 | O1 OR O2 OR O3 |
|        |     | #20 OR #28 OR #29 |
Table A1. Cont.

| Domain | No. | Search Terms |
|--------|-----|--------------|
| S      | #31 | “randomized controlled trial” [All Fields] |

Combinations

| P, I, O | #9 AND #19 AND #30 |
|--------|---------------------|
| P, I, O, S | #9 AND #19 AND #30 AND #31 |

Table A2. Search terms and search strategy in Scopus database.

| Domain | No. | Search Terms: TITLE-ABS-KEY |
|--------|-----|-------------------------------|
| P      | #1  | “breast cancer”               |
|        | #2  | “breast neoplasms”            |
| P      | #3  | #1 OR #2                      |
| P      | #4  | “human epidermal growth factor receptor 2” |
|        | #5  | “HER2”                        |
|        | #6  | “ERBB2”                       |
| P      | #7  | #4 OR #5 OR #6                |
| P      | #8  | P1 AND P2                     |
|        |     | #3 AND #7                     |
| I      | #9  | “neoadjuvant”                 |
|        | #10 | “pre operative”               |
|        | #11 | #9 OR #10                     |
| I      | #12 | “anti HER2” OR “anti human epidermal growth factor receptor 2” |
|        | #13 | “targeted therapy”            |
|        | #14 | “trastuzumab” OR “Herceptin”  |
|        | #15 | “pertuzumab” OR “perjeta”    |
|        | #16 | “lapatinib” OR “Tykerb” OR “Tyverb” |
|        | #17 | #12 OR #13 OR #14 OR #15 OR #16 |
| I      | #18 | I1 OR I2                      |
|        |     | #11 OR #17                    |
| O      | #19 | “complete response”           |
| O      | #20 | “survival”                    |
| O      | #21 | “adverse event”               |
| O      | #22 | O1 OR O2 OR O3                |
|        |     | #19 OR #20 OR #21             |
| S      | #23 | “randomized controlled trial” |

Combinations

| P, I, O | #8 AND #18 AND #22 |
|--------|---------------------|
| P, I, O, S | #8 AND #18 AND #22 AND #23 |
Table A3. Search terms and search strategy in Cochrane Central Register of Controlled Trials.

| Domain | No.  | Search Terms                                                                 | Limits    |
|--------|------|-----------------------------------------------------------------------------|-----------|
| P 1    | #1   | “breast cancer” OR “breast neoplasm”                                        |           |
| P 2    | #2   | “human epidermal growth factor receptor 2” OR “HER 2”                       | In Trials |
|        | #3   | “erbB2”                                                                     |           |
|        | #4   | #2 OR #3                                                                    |           |
| P      | #5   | P1 AND P2                                                                   | In Trials |
| I 1    | #6   | “neoadjuvant”                                                               | In Trials |
|        | #7   | “preoperative”                                                              |           |
|        | #8   | #6 OR #7                                                                    |           |
| I 2    | #9   | “anti HER2”                                                                 | In Trials |
|        | #10  | “anti human epidermal growth factor receptor 2”                             |           |
|        | #11  | “targeted therapy”                                                          |           |
|        | #12  | “trastuzumab” OR “Herceptin”                                                |           |
|        | #13  | “pertuzumab” OR “perjeta”                                                   |           |
|        | #14  | “lapatinib” OR “Tykerb”                                                     |           |
|        | #15  | #9 OR #10 OR #11 OR #12 OR #13 OR #14                                      |           |
| I      | #16  | I1 OR I2                                                                    | In Trials |
|        | #17  | “complete response”                                                         | In Trials |
| O 1    | #18  | “survival”                                                                  | In Trials |
| O 2    | #19  | “adverse event”                                                             | In Trials |
| O 3    | #20  | O1 OR O2 OR O3                                                              | In Trials |
|        |      | #17 OR #18 OR #19                                                            |           |

Combination

P, I, O - #5 AND #16 AND #20 In Trials

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
2. Pernaut, C.; Lopez, F.; Ciruelos, E. Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer. Breast Care 2018, 13, 244–249. [CrossRef] [PubMed]
3. Jiang, N.; Lin, J.-J.; Wang, J.; Zhang, B.-N.; Li, A.; Chen, Z.-Y.; Guo, S.; Li, B.-B.; Duan, Y.-Z.; Yan, R.-Y.; et al. Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs. Exp. Ther. Med. 2018, 16, 2183–2192. [CrossRef]
4. Sevcikova, K.; Vertakova-Krakovska, B.; Spanik, S. Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer. ISRN Oncol. 2013, 2013, 362467. [CrossRef]
5. Gianni, L.; Pienkowski, T.; Im, Y.H.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.A.; Pedrini, J.L.; et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016, 17, 791–800. [CrossRef]
6. Cardoso, F.K.S.; Ohno, S.; Penault-Llorca, F.; Poortmans, P.; Rubio, I.T.; Zackrisson, S.; Senkus, E.; The ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019, 30, 1674. [CrossRef]
7. National Comprehensive Cancer Network. NCCN Guidelines Invasive Breast Cancer (Version 5.2020). 2020. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed on 6 May 2021).
8. Nakashoji, A.; Hayashida, T.; Yokoe, T.; Maeda, H.; Toyota, T.; Kikuchi, M.; Watanuki, R.; Nagayama, A.; Seki, T.; Takahashi, M.; et al. The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. Cancer Treat. Rev. 2018, 62, 9–17. [CrossRef]
9. Wu, D.; Chen, T.; Jiang, H.; Duan, C.; Zhang, X.; Lin, Y.; Chen, S.; Wu, F. Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis. J. Oncol. 2019, 2019, 3406972. [CrossRef]
31. Guarnieri, V.; Frassoldati, A.; Bottini, A.; Cagossi, K.; Bisagni, G.; Sarti, S.; Ravaoli, A.; Cavanna, L.; Giardina, G.; Musolino, A.; et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J. Clin. Oncol. 2012, 30, 1989–1995. [CrossRef] [PubMed]

32. Pierga, J.Y.; Delaloge, S.; Espié, M.; Brain, E.; Sigal-Zafrani, B.; Mathieu, M.C.; Bertheau, P.; Guinebretière, J.M.; Spielmann, M.; Savignoni, A.; et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res. Treat. 2010, 122, 429–437. [CrossRef]

33. Gianni, L.; Eiermann, W.; Semiglazov, V.; Manikhas, A.; Lluch, A.; Tjulandin, S.; Sabadell, M.D.; Caballero, A.; et al. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. Eur. J. Cancer 2017, 75, 323–332. [CrossRef] [PubMed]

34. Chang, H.R.; Glaspy, J.; Allison, M.A.; Kass, F.C.; Elashoff, R.; Chung, D.U.; Gornbein, J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010, 116, 4227–4237. [CrossRef]

35. Gianni, L.; Eiermann, W.; Semiglazov, V.; Manikhas, A.; Lluch, A.; Tjulandin, S.; Zambetti, M.; Vazquez, F.; Byakhow, M.; Lichinitser, M.; et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375, 377–384.

36. Semiglazov, V.; Eiermann, W.; Zambetti, M.; Manikhas, A.; Bozhok, A.; Lluch, A.; Tjulandin, S.; Sabadell, M.D.; Caballero, A.; Valagussa, P.; et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeoAdjuvant Herceptin (NOAH) study. Eur. J. Surg. Oncol. 2011, 37, 856–863. [CrossRef]

37. Untch, M.; Loibl, S.; Bischoff, J.; Eidtmann, H.; Kaufmann, M.; Blohmer, J.U.; Hilfrich, J.; Strumberg, D.; Fasching, P.A.; Kreienberg, R.; et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol. 2012, 13, 135–144. [CrossRef]

38. Semiglazov, V.; Eiermann, W.; Zambetti, M.; Manikhas, A.; Lluch, A.; Tjulandin, S.; Sabadell, M.D.; Caballero, A.; Valagussa, P.; et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeoAdjuvant Herceptin (NOAH) study. Eur. J. Surg. Oncol. 2011, 37, 856–863. [CrossRef]

39. Untch, M.; Loibl, S.; Bischoff, J.; Eidtmann, H.; Kaufmann, M.; Blohmer, J.U.; Hilfrich, J.; Strumberg, D.; Fasching, P.A.; Kreienberg, R.; et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol. 2012, 13, 633–640. [CrossRef]

40. Baselga, J.; Bradbury, I.; Eidtmann, H.; Di Cosimo, S.; De Azambuja, E.; Aurrer, C.; Gómez, H.; Dinh, P.; Fauria, K.; Van Dooren, V.; et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379, 633–640. [CrossRef]

41. Cristiello, C.; Azim, H.A.; Agbor-tarh, D.; de Azambuja, E.; Piccart, M.; Baselga, J.; Eidtmann, H.; Di Cosimo, S.; Bradbury, I.; Rubio, I.T. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer. Results from the NeoAdjuvant Herceptin phase III trial. Ann. Oncol. 2013, 24, 1980–1985. [CrossRef]

42. Hua, C.; Baserga, J.; de Azambuja, E.; Untch, M.; Fumagalli, D.; Sart, P.; Lang, I.; Smith, I.; Boyle, F.; et al. Survival outcomes of the NeoALTTO study (BIG 1–06): Updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur. J. Cancer 2019, 118, 169–177. [CrossRef] [PubMed]

43. Robidoux, A.; Tang, G.; Rastogi, P.; Geyer, C.E.; Azar, C.A.; Atkins, J.N.; Fehrenbacher, L.; Bear, H.D.; Baez-Diaz, L.; Sarwar, S.; et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial. Lancet Oncol. 2013, 14, 1183–1192. [CrossRef]

44. Holmes, F.A.; Espina, V.; Liotta, L.A.; Nagarwala, Y.M.; Danso, M.; McIntyre, K.J.; Osborne, C.R.C.; Anderson, T.; Krekow, L.; Blum, J.L.; et al. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res. Notes 2013, 6, 507. [CrossRef]

45. Steger, G.G.; Greil, R.; Lang, A.; Rudaus, M.; Fitzal, E.; Miniciric, H.; Hartmann, B.L.; Bartsch, R.; Melbinger, E.; Hubalek, M.; et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: Final results of a randomized phase III study (ABCSG-24). Ann. Oncol. 2014, 25, 366–371. [CrossRef] [PubMed]

46. Alba, E.; Albagnac, J.; de la Haba, J.; Barnadas, A.; Calvo, L.; Sánchez-Rovira, P.; Ramos, M.; Rojo, F.; Burgués, O.; Carrasco, E.; et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GECIM/2006-14 trial. Br. J. Cancer 2014, 110, 1139–1147. [CrossRef]

47. Bonnefoi, H.; Jacot, W.; Saghatchian, M.; Moldovan, C.; Venat-Bouvet, L.; Zaman, K.; Matus, E.; Petit, T.; Bodmer, A.; Quenel-Tueux, N.; et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: Results of the randomized phase II EORTC 10054 study. Ann. Oncol. 2015, 26, 325–332. [CrossRef] [PubMed]
